Browsing by Subject "oxymetazoline"

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    A comparative analysis of the decongestive effect of oxymetazoline and xylometazoline in healthy subjects
    (2011) Eskiizmir G.; Hirçin Z.; Özyurt B.; Ünlü H.
    Background: Oxymetazoline and xylometazoline are locally effective and direct acting drugs that relieve nasal congestion. The aim of this study was to objectively determine and compare the decongestive effects of oxymetazoline and xylometazoline in healthy subjects. Methods: The study population comprised thirty healthy adults. All subjects underwent active anterior rhinomanometry (AARhm) and acoustic rhinometry (AR) tests following the application of oxymetazoline, xylometazoline, or placebo (physiological saline). The change in nasal resistance, nasal airflow, and different cross-sectional areas (CSAs) of the nasal cavity in the subjects were examined for each solution separately. The measurements were obtained over a 1-h period (baseline and 1, 15, 30, and 60 min post-dosing). All results were analyzed using the Kruskal-Wallis test and the Mann-Whitney U test. Results: A total of 6,300 measurements of AARhm and AR were obtained. The application of placebo did not cause a statistically significant change in nasal resistance, nasal airflow, and CSAs (CSA1, 2, and 3, respectively) of the nasal cavity. In contrast, statistically significant changes in nasal resistance (inspiration p=0.000 and p= 0.004; expiration p=0.000 and p=0.000), nasal airflow (inspiration p=0.000 and p= 0.004; expiration p=0.000 and p=0.000), and CSAs of the nasal cavity (CSA2 p=0.000 and p=0.000, CSA3 p=0.000 and p=0.00), with the exception of CSA1 (p= 0.982 and p=0.994), were obtained after the application of oxymetazoline and xylometazoline. A comparison of oxymetazoline and xylometazoline based on nasal resistance, nasal airflow, and CSAs of the nasal cavity demonstrated no statistically significant difference, except for CSA3. Conclusion: Oxymetazoline and xylometazoline are fast-acting and potent topical decongestants that have similar decongestive effects. © 2010 Springer-Verlag.
  • No Thumbnail Available
    Item
    Intranasal steroids or radiofrequency turbinoplasty in persistent allergic rhinitis: Effects on quality of life and objective parameters
    (2011) Gunhan K.; Unlu H.; Yuceturk A.V.; Songu M.
    Nasal congestion is a cardinal symptom of allergic rhinitis (AR). It is associated with decreased quality of life and difficult to treat as perceived by the patients. The purpose of this study is to evaluate the mid-term objective and subjective outcomes of management of nasal congestion using intranasal steroid (INS) therapy or radiofrequency turbinoplasty (RFT) in patients with persistent AR who have mucosal hypertrophy of the inferior turbinate. Fifty-five adult patients with AR, who claimed nasal congestion refractory to oral antihistamine (desloratadine) therapy, were randomized to INS (mometasone furoate) or temperature-controlled RFT treatment groups. Outcomes were determined by active anterior rhinomanometry, visual analog scale (VAS), and rhinoconjunctivitis quality of life questionnaire (RQLQ) at least 12 months after treatment. The median total nasal resistance decreased from 0.49 ± 0.17 to 0.39 ± 0.12 Pa/cm3/s (p = 0.42), and from 0.51 ± 0.18 to 0.29 ± 0.07 Pa/cm3/s (p = 0.003) with INS and RFT, respectively. RFT provided a better reduction in the perception of congestion in VAS scores. RQLQ scores improved significantly in both groups 1 year after treatment (mean follow-up 14.2 months) (p < 0.05). No adverse reactions were encountered in either group. Nasal congestion refractory to antihistamine appears to be improved by INS at some point, while reduced significantly by RFT in objective and subjective parameters. Both options are also effective in increasing the quality of life in patients with AR. RFT might be a safe and effective treatment of option in AR compared with INS. © 2010 Springer-Verlag.